Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of acylpeptide hydrolase polymorphisms on valproic acid level in Chinese epilepsy patients.

Pharmacogenomics - 1 Jul 2016

Wen Zhi Peng, Fan Shuang Shi, Du Can, Yin Tao, Zhou Bo Ting, Peng Ze Feng, Xie Yuan Yang, Zhang Wei, Chen Yao, Tang Jie, Xiao Jian, Chen Xiao Ping

Abstract excerpt

BACKGROUND: Concomitant use of meropenem (MEPM) can dramatically decrease valproic acid (VPA) plasma level. It is accepted that inhibition in acylpeptide hydrolase (APEH) activity by MEPM coadministration was the trigger of this drug-drug interaction. AIM: To investigate the influence of APEH genetic polymorphisms on VPA plasma concentration in Chinese epilepsy patients. PATIENTS & METHODS: Urinary VPA-d6...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticonvulsants
Share to Asian People

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epilepsy

Share to Glucuronosyltransferase

Share to Peptide Hydrolases

Share to Polymorphism, Genetic

Share to Polymorphism, Single Nucleotide

Share to Valproic Acid

Source

Identifiers

PMID: 27406852
DOI: 10.2217/pgs-2016-0030

Genes

APEH

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of acylpeptide hydrolase polymorphisms on valproic acid level in Chinese epilepsy patients.PMID 27406852Read ↗

Influence of UGT2B7 and UGT1A6 polymorphisms on plasma concentration to dose ratio of valproic acid in Chinese epileptic children.Semantic proximity Read ↗

Effects of UGT1A6 and GABRA1 on Standardized Valproic Acid Plasma Concentrations and Treatment Effect in Children With Epilepsy in China.Semantic proximity Read ↗

Effects of genetic polymorphism of drug-metabolizing enzymes on the plasma concentrations of antiepileptic drugs in Chinese populationSemantic proximity Read ↗

Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy.Semantic proximity Read ↗

Genetic polymorphisms and valproic acid plasma concentration in children with epilepsy on valproic acid monotherapy.Semantic proximity Read ↗

Population pharmacokinetics of valproic acid in epileptic children: Effects of clinical and genetic factors.Semantic proximity Read ↗

Impact of MDR1 and UGT Gene Polymorphisms on Sodium Valproate Plasma Concentration in Patients with Epilepsy.Semantic proximity Read ↗

Effect of CYP2C19, UGT1A8, and UGT2B7 on valproic acid clearance in children with epilepsy: a population pharmacokinetic model.Semantic proximity Read ↗

Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy.Semantic proximity Read ↗

Association of SCN1A, SCN2A, and UGT2B7 Polymorphisms with Responsiveness to Valproic Acid in the Treatment of Epilepsy.Semantic proximity Read ↗

UGT1A6- and UGT2B7-related valproic acid pharmacogenomics according to age groups and total drug concentration levels.Semantic proximity Read ↗

Effect of UGT2B7 genotypes on plasma concentration of valproic acid: a meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.